Improving Risk Assessment-Reference-Cited by-同舟云学术

Improving Risk Assessment

Published:2012-11-07 Issue:159 Volume:4 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Dambach Donna M.¹,Uppal Hirdesh¹

Affiliation:

1. Safety Assessment, Development Sciences, Genentech, South San Francisco, CA 94080, USA.

Abstract

A U.S. government initiative to engineer nonclinical cell-based models that mimic human biology may improve predictions of drug-related adverse events.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference30 articles.

1. Lessons from 60 years of pharmaceutical innovation

2. Why Drugs Fail - A Study on Side Effects in New Chemical Entities

3. Phase II failures: 2008–2010

4. Phase III and submission failures: 2007–2010

5. Food and Drug Administration Challenges and opportunities report Innovation or stagnation: Challenge and opportunity on the critical path to new medical products (2004).http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 3D Tissue-Engineered Vascular Drug Screening Platforms: Promise and Considerations;Frontiers in Cardiovascular Medicine;2022-03-04

2. Imitating Hypoxia and Tumor Microenvironment with Immune Evasion by Employing Three Dimensional In Vitro Cellular Models: Impressive Tool in Drug Discovery;Recent Patents on Anti-Cancer Drug Discovery;2022-02

3. 3D in vitro models of skeletal muscle: myopshere, myobundle and bioprinted muscle construct;Veterinary Research;2021-05-19

4. An in-vitro assay using human spermatozoa to detect toxicity of biologically active substances;Scientific Reports;2019-10-10

5. Use of porous membranes in tissue barrier and co-culture models;Lab on a Chip;2018